Stockreport

ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF The global bladder cancer market could reach $11.5 billion by 2032. Company also tends to evaluate the use of ANKTIVA towards other cancer indications such as acute m [Read more]